- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803
- Drug · Procedure · Biological
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 362
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Interventions
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT)
- Drug · Procedure · Radiation
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Disease
- Interventions
- G-CSF plus plerixafor, rituximab
- Drug · Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Occlusion
- Interventions
- Catheter-based intracoronary injection
- Biological
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Sickle Cell Disease, Hemoglobinopathies
- Interventions
- EDIT-301
- Genetic
- Lead sponsor
- Editas Medicine, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more
- Conditions
- Leukemia
- Interventions
- sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
- Biological · Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2019
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more
- Conditions
- Recurrent Oligodendroglioma, Progressive Oligodendroglioma
- Interventions
- TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Embryonal Brain Tumor Not Otherwise Specified, Ependymoma
- Interventions
- Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma, Transformed Indolent Lymphoma
- Interventions
- MDV9300
- Biological
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neuroblastoma
- Interventions
- Radiation: 131I-MIBG, Dinutuximab, Vorinostat
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Multiple Myeloma, Lymphoma, Non-Hodgkin
- Interventions
- XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 1 Diabetes
- Interventions
- Autologous UCB, Omega 3 FA, Vitamin D
- Biological · Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Multiple Myeloma
- Interventions
- High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
- Drug · Other
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- Up to 70 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
- Interventions
- Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
- Interventions
- CD30.CAR-T, Fludarabine, Bendamustine
- Drug
- Lead sponsor
- Tessa Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2037
- U.S. locations
- 5
- States / cities
- Duarte, California • Chicago, Illinois • Philadelphia, Pennsylvania + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, stem cell, Dexamethasone, Clarithromycin
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 10
- States / cities
- Basking Ridge, New Jersey • New Brunswick, New Jersey • Commack, New York + 6 more
- Conditions
- Ovarian Cancer
- Interventions
- filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
- Biological · Procedure · Radiation
- Lead sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 3
- States / cities
- Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Myeloma
- Interventions
- Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
- Biological · Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Interventions
- Lifileucel (LN-144/LN-145)
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Harrison, New York • New York, New York
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
- Biological · Procedure · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma
- Interventions
- Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- RAPA-501 Autologous T stem cells
- Other
- Lead sponsor
- Rapa Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 7 more
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- LMP2A-loaded conventional DC vaccine, DUK-CPG-001
- Biological
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan, Bortezomib
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey